Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.

Basic & clinical pharmacology & toxicology - 1 May 2020

Baumann Pierre, Eap Chin B, Gastpar Markus

Abstract excerpt

There is evidence that the antipsychotic drug perazine is an inhibitor of CYP2D6. This study aimed at evaluating its effect on CYP2D6 and CYP2C19 activities in submitting psychiatric patients to phenotyping with dextromethorphan and mephenytoin, respectively, substrates of these enzymes, before and during a treatment with perazine. A total of 31 patients were phenotyped with dextromethorphan (CYP2D6) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Dextromethorphan

Share to Drug Interactions

Share to Mephenytoin

Share to Schizophrenia

Source

Identifiers

PMID: 31814297
DOI: 10.1111/bcpt.13373

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.PMID 31814297Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.Semantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.Semantic proximity Read ↗

Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol.Semantic proximity Read ↗

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.Semantic proximity Read ↗

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.Semantic proximity Read ↗

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.Semantic proximity Read ↗

A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.